BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiao X, Nawab O, Patel T, Kossenkov AV, Halama N, Jaeger D, Pestell RG. Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology. Cancer Res 2019;79:4801-7. [PMID: 31292161 DOI: 10.1158/0008-5472.CAN-19-1167] [Cited by in Crossref: 58] [Cited by in F6Publishing: 85] [Article Influence: 19.3] [Reference Citation Analysis]
Number Citing Articles
1 Capistrano I R, Paul S, Boere I, Pantziarka P, Chopra S, Nout RA, Bouche G. Drug repurposing as a potential source of innovative therapies in cervical cancer. Int J Gynecol Cancer 2022:ijgc-2022-003585. [PMID: 36137575 DOI: 10.1136/ijgc-2022-003585] [Reference Citation Analysis]
2 Yero A, Shi T, Routy J, Tremblay C, Durand M, Costiniuk CT, Jenabian M. FoxP3+ CD8 T-cells in acute HIV infection and following early antiretroviral therapy initiation. Front Immunol 2022;13:962912. [DOI: 10.3389/fimmu.2022.962912] [Reference Citation Analysis]
3 Liu X, Wang M, Song Y, Zhang C, Jiang Y, Li W, Xu B, Jiang Z. Kukoamine A inhibits C-C motif chemokine receptor 5 to attenuate lipopolysaccharide-induced lung injury. Drug Dev Res 2022. [PMID: 35862278 DOI: 10.1002/ddr.21975] [Reference Citation Analysis]
4 Baram T, Oren N, Erlichman N, Meshel T, Ben-baruch A. Inflammation-Driven Regulation of PD-L1 and PD-L2, and Their Cross-Interactions with Protective Soluble TNFα Receptors in Human Triple-Negative Breast Cancer. Cancers 2022;14:3513. [DOI: 10.3390/cancers14143513] [Reference Citation Analysis]
5 Yousuf M, Shamsi A, Mohammad T, Azum N, Alfaifi SYM, Asiri AM, Mohamed Elasbali A, Islam A, Hassan MI, Haque QMR. Inhibiting Cyclin-Dependent Kinase 6 by Taurine: Implications in Anticancer Therapeutics. ACS Omega. [DOI: 10.1021/acsomega.2c03479] [Reference Citation Analysis]
6 Wang F, Tao Z, Tian Z, Jin J, Dong J, Dai Y, Yu W, Tang B, Hu S. CCR5 as a Prognostic Factor in Lower-Grade Glioma is Involved in the Remodeling of the Tumor Microenvironment. Front Genet 2022;13:874896. [DOI: 10.3389/fgene.2022.874896] [Reference Citation Analysis]
7 Chen K, Wang Y, Hou Y, Wang Q, Long D, Liu X, Tian X, Yang Y. Single cell RNA-seq reveals the CCL5/SDC1 receptor-ligand interaction between T cells and tumor cells in pancreatic cancer. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215834] [Reference Citation Analysis]
8 Su X, Jin H, Du N, Wang J, Lu H, Xiao J, Li X, Yi J, Gu T, Dan X, Gao Z, Li M. A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy. Front Oncol 2022;12:930589. [DOI: 10.3389/fonc.2022.930589] [Reference Citation Analysis]
9 Raghavakaimal A, Cristofanilli M, Tang C, Alpaugh RK, Gardner KP, Chumsri S, Adams DL. CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome. Breast Cancer Res 2022;24. [DOI: 10.1186/s13058-022-01528-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Haag GM, Springfeld C, Grün B, Apostolidis L, Zschäbitz S, Dietrich M, Berger A, Weber TF, Zoernig I, Schaaf M, Waberer L, Müller DW, Al-batran S, Halama N, Jaeger D. Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer – The PICCASSO phase I trial. European Journal of Cancer 2022;167:112-22. [DOI: 10.1016/j.ejca.2022.03.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Feng Y, Xu Z, Wang Y, Xiong Y, Xie W, He Y, Chen L, Liu G, Li X, Liu J, Wu Q. Targeting C–C Chemokine Receptor 5: Key to Opening the Neurorehabilitation Window After Ischemic Stroke. Front Cell Neurosci 2022;16:876342. [DOI: 10.3389/fncel.2022.876342] [Reference Citation Analysis]
12 Wieboldt R, Läubli H. Glycosoaminoglycans in cancer therapy. Am J Physiol Cell Physiol 2022. [PMID: 35385322 DOI: 10.1152/ajpcell.00063.2022] [Reference Citation Analysis]
13 Wang L, Jiang J, Chen Y, Jia Q, Chu Q. The roles of CC chemokines in response to radiation. Radiat Oncol 2022;17. [DOI: 10.1186/s13014-022-02038-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Andrea AE, Chiron A, Mallah S, Bessoles S, Sarrabayrouse G, Hacein-Bey-Abina S. Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment. Front Immunol 2022;13:830292. [PMID: 35211124 DOI: 10.3389/fimmu.2022.830292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Wang S, Yang Y, Ma P, Huang H, Tang Q, Miao H, Fang Y, Jiang N, Li Y, Zhu Q, Tao W, Zha Y, Li N. Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials. Mol Ther Oncolytics 2022;24:799-813. [PMID: 35317518 DOI: 10.1016/j.omto.2022.02.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Jasinska AJ, Pandrea I, Apetrei C. CCR5 as a Coreceptor for Human Immunodeficiency Virus and Simian Immunodeficiency Viruses: A Prototypic Love-Hate Affair. Front Immunol 2022;13:835994. [PMID: 35154162 DOI: 10.3389/fimmu.2022.835994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Sieviläinen M, Saavalainen J, Adnan-awad S, Salo T, Al-samadi A. IDO1 Inhibition Reduces Immune Cell Exclusion Through Inducing Cell Migration While PD-1 Blockage Increases IL-6 and -8 Secretion From T Cells in Head and Neck Cancer. Front Immunol 2022;13:812822. [DOI: 10.3389/fimmu.2022.812822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Erlichman N, Baram T, Meshel T, Morein D, Da'adoosh B, Ben-Baruch A. Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes. Cancers (Basel) 2022;14:1042. [PMID: 35205789 DOI: 10.3390/cancers14041042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
19 Fu L, Jin W, Zhang J, Zhu L, Lu J, Zhen Y, Zhang L, Ouyang L, Liu B, Yu H. Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions. Acta Pharm Sin B 2022;12:532-57. [PMID: 35256933 DOI: 10.1016/j.apsb.2021.09.006] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Aznauryan E, Yermanos A, Kinzina E, Devaux A, Kapetanovic E, Milanova D, Church GM, Reddy ST. Discovery and validation of human genomic safe harbor sites for gene and cell therapies. Cell Rep Methods 2022;2:100154. [PMID: 35474867 DOI: 10.1016/j.crmeth.2021.100154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Deng J, Fleming JB. Inflammation and Myeloid Cells in Cancer Progression and Metastasis. Front Cell Dev Biol 2022;9:759691. [DOI: 10.3389/fcell.2021.759691] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 DiNatale A, Kaur R, Qian C, Zhang J, Marchioli M, Ipe D, Castelli M, McNair CM, Kumar G, Meucci O, Fatatis A. Subsets of cancer cells expressing CX3CR1 are endowed with metastasis-initiating properties and resistance to chemotherapy. Oncogene 2022. [PMID: 34999735 DOI: 10.1038/s41388-021-02174-w] [Reference Citation Analysis]
23 Raza S, Rajak S, Tewari A, Gupta P, Chattopadhyay N, Sinha RA, Chakravarti B. Multifaceted role of chemokines in solid tumors: From biology to therapy. Semin Cancer Biol 2022:S1044-579X(21)00304-7. [PMID: 34979274 DOI: 10.1016/j.semcancer.2021.12.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
24 Chen Q, He L, Li X, Xu L, Chen T. Ruthenium complexes boost NK cell immunotherapy via sensitizing triple-negative breast cancer and shaping immuno-microenvironment. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121371] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
25 Fathi M, Vakili K, Jazi K, Sadeghi MA, Hajiesmaeili M, Mohamadkhani A, Rezaei-Tavirani M, Tavasol A. Challenges of cancer immunotherapy and chemotherapy during the COVID-19 pandemic. Tumori 2021;:3008916211063939. [PMID: 34918602 DOI: 10.1177/03008916211063939] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Karin N. Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones? Cancers (Basel) 2021;13:6317. [PMID: 34944943 DOI: 10.3390/cancers13246317] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
27 Chang XL, Wu HL, Webb GM, Tiwary M, Hughes C, Reed JS, Hwang J, Waytashek C, Boyle C, Pessoa C, Sylwester AW, Morrow D, Belica K, Fischer M, Kelly S, Pourhassan N, Bochart RM, Smedley J, Recknor CP, Hansen SG, Sacha JB. CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab. Front Immunol 2021;12:794638. [PMID: 34868084 DOI: 10.3389/fimmu.2021.794638] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
28 Matsuo K, Yoshie O, Nakayama T. Multifaceted Roles of Chemokines and Chemokine Receptors in Tumor Immunity. Cancers (Basel) 2021;13:6132. [PMID: 34885241 DOI: 10.3390/cancers13236132] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
29 Tommasi S, Pabustan N, Li M, Chen Y, Siegmund KD, Besaratinia A. A novel role for vaping in mitochondrial gene dysregulation and inflammation fundamental to disease development. Sci Rep 2021;11:22773. [PMID: 34815430 DOI: 10.1038/s41598-021-01965-1] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
30 Cherney RJ, Anjanappa P, Selvakumar K, Batt DG, Brown GD, Rose AV, Vuppugalla R, Chen J, Pang J, Xu S, Yarde M, Tebben AJ, Paidi VR, Cvijic ME, Mathur A, Barrish JC, Mandlekar S, Zhao Q, Carter PH. BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate. ACS Med Chem Lett 2021;12:1753-8. [PMID: 34795864 DOI: 10.1021/acsmedchemlett.1c00373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Jansen M, Beaumelle B. How palmitoylation affects trafficking and signaling of membrane receptors. Biol Cell 2021. [PMID: 34738237 DOI: 10.1111/boc.202100052] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Wang X, Su W, Tang D, Jing J, Xiong J, Deng Y, Liu H, Ma W, Liu Z, Zhang Q. An Immune-Related Gene Prognostic Index for Triple-Negative Breast Cancer Integrates Multiple Aspects of Tumor-Immune Microenvironment. Cancers (Basel) 2021;13:5342. [PMID: 34771505 DOI: 10.3390/cancers13215342] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Patra S, Elahi N, Armorer A, Arunachalam S, Omala J, Hamid I, Ashton AW, Joyce D, Jiao X, Pestell RG. Mechanisms Governing Metabolic Heterogeneity in Breast Cancer and Other Tumors. Front Oncol 2021;11:700629. [PMID: 34631530 DOI: 10.3389/fonc.2021.700629] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Bule P, Aguiar SI, Aires-Da-Silva F, Dias JNR. Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy. Int J Mol Sci 2021;22:9804. [PMID: 34575965 DOI: 10.3390/ijms22189804] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
35 Chengcheng L, Wenwen Q, Ningyue G, Fangyuan Z, Runtong X, Zhenxiao T, Fenglei X, Yiming Q, Miaoqing Z, Xiaoming L, Ming X. Identification of the Immune-Related Genes in Tumor Microenvironment That Associated With the Recurrence of Head and Neck Squamous Cell Carcinoma. Front Cell Dev Biol 2021;9:723721. [PMID: 34490269 DOI: 10.3389/fcell.2021.723721] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Zeng Z, Lan T, Wei Y, Wei X. CCL5/CCR5 axis in human diseases and related treatments. Genes Dis 2021. [PMID: 34514075 DOI: 10.1016/j.gendis.2021.08.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
37 Mowat C, Mosley SR, Namdar A, Schiller D, Baker K. Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN-driven CCL5 and CXCL10. J Exp Med 2021;218:e20210108. [PMID: 34297038 DOI: 10.1084/jem.20210108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
38 Zhang XN, Yang KD, Chen C, He ZC, Wang QH, Feng H, Lv SQ, Wang Y, Mao M, Liu Q, Tan YY, Wang WY, Li TR, Che LR, Qin ZY, Wu LX, Luo M, Luo CH, Liu YQ, Yin W, Wang C, Guo HT, Li QR, Wang B, Chen W, Wang S, Shi Y, Bian XW, Ping YF. Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling. Cell Res 2021. [PMID: 34239070 DOI: 10.1038/s41422-021-00528-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
39 Cai C, Long J, Huang Q, Han Y, Peng Y, Guo C, Liu S, Chen Y, Shen E, Long K, Wang X, Yu J, Shen H, Zeng S. M6A "Writer" Gene METTL14: A Favorable Prognostic Biomarker and Correlated With Immune Infiltrates in Rectal Cancer. Front Oncol 2021;11:615296. [PMID: 34221955 DOI: 10.3389/fonc.2021.615296] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
40 Jiao X, Tian L, Zhang Z, Balcerek J, Kossenkov AV, Casimiro MC, Wang C, Liu Y, Ertel A, Soccio RE, Chen ER, Liu Q, Ashton AW, Tong W, Pestell RG. Pparγ1 Facilitates ErbB2-Mammary Adenocarcinoma in Mice. Cancers (Basel) 2021;13:2171. [PMID: 33946495 DOI: 10.3390/cancers13092171] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Rabaan AA, Al-Ahmed SH, Muhammad J, Khan A, Sule AA, Tirupathi R, Mutair AA, Alhumaid S, Al-Omari A, Dhawan M, Tiwari R, Sharun K, Mohapatra RK, Mitra S, Bilal M, Alyami SA, Emran TB, Moni MA, Dhama K. Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm. Vaccines (Basel) 2021;9:436. [PMID: 33946736 DOI: 10.3390/vaccines9050436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 54] [Article Influence: 4.0] [Reference Citation Analysis]
42 El-Zohairy MA, Zlotos DP, Berger MR, Adwan HH, Mandour YM. Discovery of Novel CCR5 Ligands as Anticolorectal Cancer Agents by Sequential Virtual Screening. ACS Omega 2021;6:10921-35. [PMID: 34056245 DOI: 10.1021/acsomega.1c00681] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Lah Turnšek T, Jiao X, Novak M, Jammula S, Cicero G, Ashton AW, Joyce D, Pestell RG. An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5. Int J Mol Sci 2021;22:4464. [PMID: 33923334 DOI: 10.3390/ijms22094464] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
44 Chen Q, Wang S, Lang JH. Development and validation of nomogram with tumor microenvironment-related genes and clinical factors for predicting overall survival of endometrial cancer. J Cancer 2021;12:3530-8. [PMID: 33995630 DOI: 10.7150/jca.51493] [Reference Citation Analysis]
45 Mehta AK, Kadel S, Townsend MG, Oliwa M, Guerriero JL. Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer. Front Immunol 2021;12:643771. [PMID: 33968034 DOI: 10.3389/fimmu.2021.643771] [Cited by in Crossref: 3] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
46 Cendrowicz E, Sas Z, Bremer E, Rygiel TP. The Role of Macrophages in Cancer Development and Therapy. Cancers (Basel) 2021;13:1946. [PMID: 33919517 DOI: 10.3390/cancers13081946] [Cited by in F6Publishing: 30] [Reference Citation Analysis]
47 Kumar A, Singh R, Kaur J, Pandey S, Sharma V, Thakur L, Sati S, Mani S, Asthana S, Sharma TK, Chaudhuri S, Bhattacharyya S, Kumar N. Wuhan to World: The COVID-19 Pandemic. Front Cell Infect Microbiol 2021;11:596201. [PMID: 33859951 DOI: 10.3389/fcimb.2021.596201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
48 Rubinstein-Achiasaf L, Morein D, Ben-Yaakov H, Liubomirski Y, Meshel T, Elbaz E, Dorot O, Pichinuk E, Gershovits M, Weil M, Ben-Baruch A. Persistent Inflammatory Stimulation Drives the Conversion of MSCs to Inflammatory CAFs That Promote Pro-Metastatic Characteristics in Breast Cancer Cells. Cancers (Basel) 2021;13:1472. [PMID: 33806906 DOI: 10.3390/cancers13061472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
49 Tabana Y, Okoye IS, Siraki A, Elahi S, Barakat KH. Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis. Front Oncol 2021;11:628138. [PMID: 33747948 DOI: 10.3389/fonc.2021.628138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
50 Kohli K, Pillarisetty VG, Kim TS. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther 2021. [PMID: 33603130 DOI: 10.1038/s41417-021-00303-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
51 Devadoss D, Singh SP, Acharya A, Do KC, Periyasamy P, Manevski M, Mishra N, Tellez CS, Ramakrishnan S, Belinsky SA, Byrareddy SN, Buch S, Chand HS, Sopori M. HIV-1 Productively Infects and Integrates in Bronchial Epithelial Cells. Front Cell Infect Microbiol 2020;10:612360. [PMID: 33614527 DOI: 10.3389/fcimb.2020.612360] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
52 Baram T, Rubinstein-Achiasaf L, Ben-Yaakov H, Ben-Baruch A. Inflammation-Driven Breast Tumor Cell Plasticity: Stemness/EMT, Therapy Resistance and Dormancy. Front Oncol 2020;10:614468. [PMID: 33585241 DOI: 10.3389/fonc.2020.614468] [Cited by in Crossref: 4] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
53 Jiao X, Wang M, Zhang Z, Li Z, Ni D, Ashton AW, Tang HY, Speicher DW, Pestell RG. Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. Breast Cancer Res 2021;23:11. [PMID: 33485378 DOI: 10.1186/s13058-021-01391-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
54 Bányai L, Trexler M, Kerekes K, Csuka O, Patthy L. Use of signals of positive and negative selection to distinguish cancer genes and passenger genes. Elife 2021;10:e59629. [PMID: 33427197 DOI: 10.7554/eLife.59629] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
55 Sulochana SP, Trivedi RK, Srinivas NR, Mullangi R. A concise review of bioanalytical methods of small molecule immuno-oncology drugs in cancer therapy. Biomed Chromatogr 2021;35:e4996. [PMID: 33047346 DOI: 10.1002/bmc.4996] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Rao J, Wu X, Zhou X, Deng R, Ma Y. TMEM205 Is an Independent Prognostic Factor and Is Associated With Immune Cell Infiltrates in Hepatocellular Carcinoma. Front Genet 2020;11:575776. [PMID: 33193690 DOI: 10.3389/fgene.2020.575776] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
57 Mehlotra RK. Chemokine receptor gene polymorphisms and COVID-19: Could knowledge gained from HIV/AIDS be important? Infect Genet Evol 2020;85:104512. [PMID: 32858232 DOI: 10.1016/j.meegid.2020.104512] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
58 Kothari C, Diorio C, Durocher F. The Importance of Breast Adipose Tissue in Breast Cancer. Int J Mol Sci 2020;21:E5760. [PMID: 32796696 DOI: 10.3390/ijms21165760] [Cited by in Crossref: 16] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
59 Caligiuri A, Pastore M, Lori G, Raggi C, Di Maira G, Marra F, Gentilini A. Role of Chemokines in the Biology of Cholangiocarcinoma. Cancers (Basel) 2020;12:E2215. [PMID: 32784743 DOI: 10.3390/cancers12082215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
60 Fakhouri EW, Peterson SJ, Kothari J, Alex R, Shapiro JI, Abraham NG. Genetic Polymorphisms Complicate COVID-19 Therapy: Pivotal Role of HO-1 in Cytokine Storm. Antioxidants (Basel) 2020;9:E636. [PMID: 32708430 DOI: 10.3390/antiox9070636] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
61 Aldinucci D, Borghese C, Casagrande N. The CCL5/CCR5 Axis in Cancer Progression. Cancers (Basel) 2020;12:E1765. [PMID: 32630699 DOI: 10.3390/cancers12071765] [Cited by in Crossref: 34] [Cited by in F6Publishing: 68] [Article Influence: 17.0] [Reference Citation Analysis]
62 Liubomirski Y, Ben-Baruch A. Notch-Inflammation Networks in Regulation of Breast Cancer Progression. Cells 2020;9:E1576. [PMID: 32605277 DOI: 10.3390/cells9071576] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
63 Novak M, Koprivnikar Krajnc M, Hrastar B, Breznik B, Majc B, Mlinar M, Rotter A, Porčnik A, Mlakar J, Stare K, Pestell RG, Lah Turnšek T. CCR5-Mediated Signaling Is Involved in Invasion of Glioblastoma Cells in Its Microenvironment. Int J Mol Sci 2020;21:E4199. [PMID: 32545571 DOI: 10.3390/ijms21124199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
64 Wu Y, Lin L, Liu X. Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors. Dis Markers 2020;2020:7291586. [PMID: 32587640 DOI: 10.1155/2020/7291586] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
65 Morein D, Erlichman N, Ben-Baruch A. Beyond Cell Motility: The Expanding Roles of Chemokines and Their Receptors in Malignancy. Front Immunol. 2020;11:952. [PMID: 32582148 DOI: 10.3389/fimmu.2020.00952] [Cited by in Crossref: 17] [Cited by in F6Publishing: 41] [Article Influence: 8.5] [Reference Citation Analysis]
66 Asokan I, Rabadia SV, Yang EH. The COVID-19 Pandemic and its Impact on the Cardio-Oncology Population. Curr Oncol Rep 2020;22:60. [PMID: 32462289 DOI: 10.1007/s11912-020-00945-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
67 Huffman AP, Lin JH, Kim SI, Byrne KT, Vonderheide RH. CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity. JCI Insight 2020;5:137263. [PMID: 32324594 DOI: 10.1172/jci.insight.137263] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
68 Chary MA, Barbuto AF, Izadmehr S, Hayes BD, Burns MM. COVID-19: Therapeutics and Their Toxicities. J Med Toxicol 2020;16:284-94. [PMID: 32356252 DOI: 10.1007/s13181-020-00777-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 52] [Article Influence: 18.5] [Reference Citation Analysis]
69 Singh SK, Mishra MK, Rivers BM, Gordetsky JB, Bae S, Singh R. Biological and Clinical Significance of the CCR5/CCL5 Axis in Hepatocellular Carcinoma. Cancers (Basel). 2020;12. [PMID: 32260550 DOI: 10.3390/cancers12040883] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
70 Kang C, Jeong SY, Song SY, Choi EK. The emerging role of myeloid-derived suppressor cells in radiotherapy. Radiat Oncol J 2020;38:1-10. [PMID: 32229803 DOI: 10.3857/roj.2019.00640] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
71 Alame M, Cornillot E, Cacheux V, Tosato G, Four M, De Oliveira L, Gofflot S, Delvenne P, Turtoi E, Cabello-Aguilar S, Nishiyama M, Turtoi A, Costes-Martineau V, Colinge J. The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities. Theranostics 2020;10:4383-94. [PMID: 32292502 DOI: 10.7150/thno.42986] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
72 Mu W, Provaznik J, Hackert T, Zöller M. Tspan8-Tumor Extracellular Vesicle-Induced Endothelial Cell and Fibroblast Remodeling Relies on the Target Cell-Selective Response. Cells 2020;9:E319. [PMID: 32013145 DOI: 10.3390/cells9020319] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
73 Kranjc MK, Novak M, Pestell RG, Lah TT. Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme. Radiol Oncol 2019;53:397-406. [PMID: 31747383 DOI: 10.2478/raon-2019-0057] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]